Literature DB >> 11018528

Sphingosylphosphorylcholine induces Ca(2+)-sensitization of vascular smooth muscle contraction: possible involvement of rho-kinase.

N Todoroki-Ikeda1, Y Mizukami, K Mogami, T Kusuda, K Yamamoto, T Miyake, M Sato, S Suzuki, H Yamagata, Y Hokazono, S Kobayashi.   

Abstract

Sphingosylphosphorylcholine (SPC), a sphingolipid, concentration-dependently (1-50 microM) induced contraction and slight elevation of the cytosolic Ca(2+) concentration ([Ca(2+)](i)) in smooth muscle of the pig coronary artery, the result being a marked increase in the force/[Ca(2+)](i) ratio. In alpha-toxin- or beta-escin-permeabilized, but not Triton X-100-permeabilized, vascular strips, SPC induced contraction at constant [Ca(2+)](i) (pCa 6.3) in the absence of GTP, whereas a G-protein-coupled receptor agonist, histamine, required the presence of GTP to induce the contraction. The Rho-kinase blocker, Y-27632 (10 microM) abolished the SPC-induced Ca(2+)-sensitization, without affecting the Ca(2+)-induced contraction. These results suggest that SPC induces Ca(2+)-sensitization of force in vascular smooth muscle, presumably through the activation of Rho-kinase (or a related kinase).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11018528     DOI: 10.1016/s0014-5793(00)02046-9

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  17 in total

1.  Sivelestat relaxes vascular smooth muscle contraction in human gastric arteries.

Authors:  Hiroko Amemori; Yoshinori Maeda; Arisu Torikai; Mikio Nakashima
Journal:  J Physiol Biochem       Date:  2011-07-14       Impact factor: 4.158

2.  Involvement of Rho kinase and protein kinase C in carbachol-induced calcium sensitization in beta-escin skinned rat and guinea-pig bladders.

Authors:  N Tugba Durlu-Kandilci; Alison F Brading
Journal:  Br J Pharmacol       Date:  2006-06       Impact factor: 8.739

Review 3.  Signal transduction underlying the vascular effects of sphingosine 1-phosphate and sphingosylphosphorylcholine.

Authors:  Denise G Hemmings
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-04       Impact factor: 3.000

Review 4.  Emerging roles of sphingosylphosphorylcholine in modulating cardiovascular functions and diseases.

Authors:  Di Ge; Hong-Wei Yue; Hong-Hong Liu; Jing Zhao
Journal:  Acta Pharmacol Sin       Date:  2018-07-26       Impact factor: 6.150

5.  Calcium sensitization induced by sodium fluoride in permeabilized rat mesenteric arteries.

Authors:  Enyue Yang; Joon Yong Cho; Uy Dong Sohn; In Kyeom Kim
Journal:  Korean J Physiol Pharmacol       Date:  2010-02-28       Impact factor: 2.016

Review 6.  Cardiovascular effects of sphingosine-1-phosphate and other sphingomyelin metabolites.

Authors:  Astrid E Alewijnse; Stephan L M Peters; Martin C Michel
Journal:  Br J Pharmacol       Date:  2004-10-25       Impact factor: 8.739

7.  Sphingolipids differentially regulate mitogen-activated protein kinases and intracellular Ca2+ in vascular smooth muscle: effects on CREB activation.

Authors:  Fiona A Mathieson; Graeme F Nixon
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

8.  3',4'-Dihydroxyflavonol reduces vascular contraction through Ca²⁺ desensitization in permeabilized rat mesenteric artery.

Authors:  Hye Young Kim; Young Mi Seok; Owen L Woodman; Spencer J Williams; In Kyeom Kim
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-10-14       Impact factor: 3.000

9.  Augmented sphingosylphosphorylcholine-induced Ca2+-sensitization of mesenteric artery contraction in spontaneously hypertensive rat.

Authors:  Sung-Kyung Ryu; Duck Sun Ahn; Young-Eun Cho; Soo-Kyung Choi; Young-Hwan Kim; Kathleen G Morgan; Young-Ho Lee
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-03-07       Impact factor: 3.000

10.  Comparison of signalling mechanisms involved in rat mesenteric microvessel contraction by noradrenaline and sphingosylphosphorylcholine.

Authors:  Christoph Altmann; Veronika Steenpass; Peter Czyborra; Peter Hein; Martin C Michel
Journal:  Br J Pharmacol       Date:  2003-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.